Hishida Asahi, Okugawa Yoshinaga, Morimoto Yuhki, Shirai Yumiko, Okamoto Kyoko, Momokita Sachiko, Ogawa Aki, Tanaka Koji, Nishikawa Ryutaro, Toiyama Yuji, Inoue Yasuhiro, Sakurai Hiroyuki, Urata Hisashi, Tanaka Motoyoshi, McMillan Donald C, Miki Chikao
Department of Preventive Medicine, Nagoya University Graduate School of Medicine, Nagoya, Aichi 466-8550, Japan.
Department of Surgery, Iga City General Hospital, Iga, Mie 518-0823, Japan.
Oncol Lett. 2019 Jan;17(1):623-629. doi: 10.3892/ol.2018.9614. Epub 2018 Oct 24.
Gastrointestinal cancer is one of the most common causes of mortality globally. The present study examined the influence of cytokine genetic polymorphisms [interleukin ( C-31T, VNTR, C-634G, T-251A, T-819C and A-1082G] on clinical outcomes in patients with gastrointestinal cancer in palliative care. A total of 59 patients with gastrointestinal cancer who were admitted to Iga City General Hospital were analyzed. Genotyping was conducted using a polymerase chain reaction with confronting two-pair primers. Patients with at least one allele demonstrated a significantly better survival (P=0.0275) while those with -634 demonstrated a worse survival (P=0.0024). Multivariate analyses using the Cox proportional hazard model revealed that those with at least one allele, -634 or -1082 had a significantly elevated adjusted hazard ratio of 9.20 (P=0.014), 41.01 (P=0.001) or 6.49 (P=0.046), respectively, compared with those with each homozygous wild-type polymorphism. In addition, the evaluation of weight loss by genotype revealed the potential influence of T-819C genotype (P=0.072). and polymorphisms were associated with the survival of patients with gastrointestinal cancer, suggesting the clinical feasibility of genetic testing in patients with gastrointestinal cancer in palliative care.
胃肠道癌是全球最常见的死亡原因之一。本研究探讨了细胞因子基因多态性[白细胞介素（C-31T、VNTR、C-634G、T-251A、T-819C和A-1082G）]对姑息治疗中胃肠道癌患者临床结局的影响。对伊贺市综合医院收治的59例胃肠道癌患者进行了分析。采用两对引物对聚合酶链反应进行基因分型。至少有一个等位基因的患者生存率显著更高（P=0.0275），而携带-634的患者生存率更差（P=0.0024）。使用Cox比例风险模型进行的多变量分析显示，与每种纯合野生型多态性的患者相比，至少有一个等位基因、-634或-1082的患者调整后的风险比分别显著升高至9.20（P=0.014）、41.01（P=0.001）或6.49（P=0.046）。此外，按基因型对体重减轻进行评估显示T-819C基因型具有潜在影响（P=0.072）。并且多态性与胃肠道癌患者的生存相关，提示在姑息治疗的胃肠道癌患者中进行基因检测具有临床可行性。
